Tarsa Therapeutics Announces Addition of Senior Level Clinical and Regulatory Expertise

PHILADELPHIA, Feb. 18 PRNewswire -- Tarsa Therapeutics, Inc. today announced the addition of two executives to its senior management team. David Krause, M.D., F.A.C.P., has joined as Chief Medical Officer and Thomas C. Wicks, Ph.D., has joined as Vice President Global Regulatory...

For the Treatment of Moderate to Severe Alzheimer’s Disease, a Combination Treatment That Delays Nursing Home Admission Would Earn Higher Patient Share in the U.S. Than Europe

WALTHAM, Mass., Feb. 17, /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19...

Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations

LAWRENCEVILLE, N.J., Feb. 16 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Wayne S. Mulcahy, Ph.D., has joined the company as Vice President, Clinical Operations. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan...

Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer

Monoclonal Antibody Adds Early-Stage Biologic to Abbott's Oncology Pipeline ABBOTT PARK, Ill. and CASTRES, France, Feb. 1 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer. cMet protein plays a role in the progression of...

Seroquel and Seroquel XR Will Garner Nearly One Quarter of Antipsychotics Sales for Major Depressive Disorder By 2013, Following Seroquel XR’s Approval as an Adjunctive Therapy for the Indication

In the news release, Seroquel and Seroquel XR Will Garner Nearly One Quarter of Antipsychotics Sales for Major Depressive Disorder By 2013, Following Seroquel XR’s Approval as an Adjunctive Therapy for the Indication issued on January 27 by Decision Resources over PR Newswire, we are advised...

AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments

AstraZeneca and Dako Denmark A/S announced today that they have entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development. Under the agreement, the companies will work together to develop diagnostic tests to help physicians determine the most appropriate cancer treatment for patients. The financial terms of the deal were not disclosed. The...

Celgene/Nippon Kayaku’s Calsed Will Become Decision Resources’ New Clinical Gold Standard in 2013 for the Treatment of Extensive-Disease Small-Cell Lung Cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene/Nippon Kayaku's Calsed earns Decision Resources' proprietary clinical gold standard status in 2013 for the treatment of extensive-disease small-cell lung cancer, following its approval for the indication in 2012. Calsed has competitive advantages over other drugs used in the second-line setting in efficacy, safety and tolerability, and delivery. "Calsed has...